FAAH is an enzyme, not an experience

Fatty acid amide hydrolase, usually shortened to FAAH, breaks down several signaling lipids, including anandamide. The enzyme can be studied with purified-protein assays, activity-based probes, tissue measurements and changes in lipid concentrations. These measurements describe molecular events. They do not, by themselves, describe how a person will feel or whether a product will achieve a useful outcome.

That distinction matters because endocannabinoid-related language is often compressed into broad terms such as balance or tone. A rigorous description identifies the exact substrate, tissue, time point and intervention. It also states whether the observation is biochemical, cellular, animal or human. Without those coordinates, two statements that sound similar can carry very different evidentiary weight.

Potency and duration are only the beginning

PF-04457845 became an important reference because it demonstrated potent, orally bioavailable and selective FAAH inhibition. Covalent or irreversible mechanisms create special measurement requirements: occupancy can persist after circulating concentrations fall, so exposure, enzyme recovery and dose timing must be modeled together. A single concentration cannot describe the full pharmacology.

Selectivity also requires more than a short receptor panel. Activity-based protein profiling can reveal interactions across enzyme families in native biological material. The BIA 10-2474 investigation showed why exact-compound profiling and metabolite analysis matter. Safety conclusions cannot be transferred from a target name or from another inhibitor that happens to share that target.

Target engagement did not guarantee clinical benefit

In a randomized osteoarthritis study, PF-04457845 produced extensive FAAH inhibition and increased fatty-acid amides, yet the reported clinical analgesic endpoint did not separate meaningfully from placebo. This is a high-value scientific result because it breaks a tempting but invalid implication: strong target engagement does not force a desired human outcome.

There are several possible points of separation. The selected condition may not depend sufficiently on the pathway; the relevant compartment may differ; biomarker change may not reach the necessary causal node; or the endpoint may respond differently than expected. The correct response is not to erase the mechanism, but to design experiments that identify which link in the chain holds.

How C2 is represented in NOVA-4

C2 is a research axis, not a finished efficacy statement. The NOVA-4 object model assigns separate fields to exact identity, human FAAH potency, proteome selectivity, active metabolites, unbound tissue distribution, target engagement and factorial contribution when combined with C1 and C3. No one field substitutes for the others.

This decomposition makes the project easier to test and harder to overstate. A laboratory can deliver a measurement packet for one predicate, and the compiler can certify exactly what changed. Public educational material can then explain established FAAH biology while keeping candidate-specific outcomes tied to candidate-specific evidence.